Oncolytic viral vectors and uses thereof
AssigneeOncorus, Inc.
InventorsMitchell H. FINER, Lorena LERNER, Christophe QUÉVA, Edward KENNEDY
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
Claims37
-21. (canceled)
A recombinant oncolytic herpes simplex virus (HSV) comprising:
- (i) a first microRNA (miRNA) target sequence cassette (miR-TS cassette) inserted into a first viral gene and comprising at least 2 target sequences for each of miR-124, miR-1, and miR-143;
- (ii) a second miR-TS cassette inserted into a second viral gene and comprising at least 2 target sequences for each of miR-128, miR-219a, and miR-122;
- and
- (iii) a third miR-TS cassette inserted into a third viral gene and comprising at least 2 target sequences for each of miR-219a, miR-204, and miR-128.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-101. (canceled)
(canceled)
(canceled)
-118. (canceled)
Dependencies are inferred from the claim text.